Cordlife (SGX:P8A) received letters of demand from two groups of persons for cord blood units stored with the company, according to a filing with the Singapore Exchange on Tuesday.
The persons claim that the cord blood units stored by the company are either unlikely to be suitable for stem cell transplant purposes or fall within the low risk or unaffected category, and have requested compensation.
The company is now seeking legal advice and will respond to the solicitors of the two persons in due course.